Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. has reported a year-over-year growth of 2% in EsoGuard test volume for Q3 2025, reaching 2,841 tests, indicating a steady demand for its diagnostic products. The company's ongoing initiatives to broaden coverage for EsoGuard through various payers, including Medicare, are anticipated to boost revenue growth significantly as it commercializes its offerings further. Additionally, a positive outcome from the recent MolDX CAC meeting suggests favorable prospects for Medicare coverage, which could enhance the company’s market penetration and potential for revenue growth, offering a compelling upside.

Bears say

The financial health of Lucid Diagnostics Inc. appears tenuous, as the company reported a consensus revenue miss for 3Q25, indicating potential challenges in market adoption of its flagship product, EsoGuard. The pro forma net loss of $10.3 million, coupled with a stable cash burn and only $47 million in pro forma cash, raises concerns regarding the company's liquidity and operational efficiency. Additionally, ongoing risks include slow adoption rates, potential difficulties in obtaining insurance reimbursements, and increased competition, all contributing to a broader negative outlook on the company's financial viability.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.